Signal Advisors Wealth LLC Purchases 5,876 Shares of Merck & Co., Inc. $MRK

Signal Advisors Wealth LLC increased its position in Merck & Co., Inc. (NYSE:MRK) by 142.3% in the first quarter, Holdings Channel.com reports. The fund owned 10,005 shares of the company’s stock after purchasing an additional 5,876 shares during the period. Signal Advisors Wealth LLC’s holdings in Merck & Co., Inc. were worth $1,203,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Kingdom Financial Group LLC. purchased a new position in shares of Merck & Co., Inc. in the fourth quarter worth $25,000. Abound Financial LLC purchased a new stake in shares of Merck & Co., Inc. during the fourth quarter valued at $26,000. Prosperity Bancshares Inc bought a new stake in Merck & Co., Inc. in the 4th quarter worth about $26,000. United Financial Planning Group LLC bought a new stake in Merck & Co., Inc. in the 3rd quarter worth about $31,000. Finally, High Note Wealth LLC raised its position in Merck & Co., Inc. by 58.9% in the 4th quarter. High Note Wealth LLC now owns 294 shares of the company’s stock worth $31,000 after buying an additional 109 shares during the last quarter. 76.07% of the stock is owned by institutional investors.

Merck & Co., Inc. Stock Performance

Shares of NYSE MRK opened at $119.71 on Wednesday. The firm has a 50 day moving average of $115.76 and a 200 day moving average of $113.91. The company has a current ratio of 1.30, a quick ratio of 1.06 and a debt-to-equity ratio of 1.02. The firm has a market capitalization of $295.66 billion, a price-to-earnings ratio of 33.72, a price-to-earnings-growth ratio of 2.60 and a beta of 0.21. Merck & Co., Inc. has a 12-month low of $76.66 and a 12-month high of $125.14.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share for the quarter, topping the consensus estimate of ($1.47) by $0.19. The business had revenue of $16.29 billion for the quarter, compared to the consensus estimate of $15.85 billion. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. The company’s quarterly revenue was up 4.9% on a year-over-year basis. During the same period last year, the firm earned $2.22 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. On average, research analysts anticipate that Merck & Co., Inc. will post 5.17 earnings per share for the current year.

Merck & Co., Inc. Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, July 8th. Investors of record on Monday, June 15th will be given a dividend of $0.85 per share. The ex-dividend date is Monday, June 15th. This represents a $3.40 annualized dividend and a yield of 2.8%. Merck & Co., Inc.’s payout ratio is 95.77%.

Key Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck said tulisokibart met its primary and key secondary endpoints in the Phase 3 ATLAS-UC induction study for moderately to severely active ulcerative colitis, strengthening confidence in a potentially important new immunology asset. Merck’s Anti-TL1A Antibody Meets Goal in Ulcerative Colitis Study
• Positive Sentiment: The tulisokibart result adds to Merck’s recent pipeline momentum and gives investors another potential growth driver as the company looks to diversify sales away from Keytruda over time. Merck’s bowel disease drug meets main goal in late-stage trial
• Positive Sentiment: Merck also recently won FDA expansion approvals for KEYTRUDA/KEYTRUDA QLEX with WELIREG in kidney cancer and for CAPVAXIVE in higher-risk children and adolescents, reinforcing near-term commercial strength across multiple franchises. Merck (MRK) Wins FDA Expansions, Posts HIV Data, And Ends Lung Cancer Trial

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on MRK shares. UBS Group raised their price target on shares of Merck & Co., Inc. from $130.00 to $145.00 and gave the company a “buy” rating in a report on Monday, April 13th. Royal Bank Of Canada restated an “outperform” rating and issued a $142.00 target price on shares of Merck & Co., Inc. in a report on Monday, March 30th. JPMorgan Chase & Co. boosted their target price on shares of Merck & Co., Inc. from $125.00 to $135.00 and gave the company an “overweight” rating in a research note on Monday, April 6th. Wall Street Zen raised Merck & Co., Inc. from a “hold” rating to a “buy” rating in a report on Saturday, June 6th. Finally, Citigroup started coverage on Merck & Co., Inc. in a research note on Wednesday, May 6th. They issued a “neutral” rating and a $125.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and seven have given a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $128.18.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.